Showing 1 - 14 results of 14 for search 'Jianming Xu', query time: 0.03s
Refine Results
-
1
Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects by Sisi Ye, Juan Li, Jianming Xu
Published 2025-01-01Get full text
Article -
2
-
3
Agriculture increases potential health risks of vertebrate viruses in soils by Kankan Zhao, Yiling Wang, Ran Xue, Xingmei Liu, Bin Ma, Jianming Xu
Published 2025-06-01Get full text
Article -
4
Prevalence and Risk Factors for Adult Cataract in the Jingan District of Shanghai by Yingying Hong, Yang Sun, Xiaofang Ye, Yi Lu, Jianjiang Xu, Jianming Xu, Yinghong Ji
Published 2022-01-01Get full text
Article -
5
-
6
-
7
-
8
Ambient Atmospheric Aerosol Extinction Coefficient Reconstruction from PM2.5 Mass Concentrations and Application to Haze Identification in China by Lina Gao, Peng Yan, Jietai Mao, Xiaochun Zhang, Xiaoling Zhang, Yongxue Wu, Junshan Jing, Jianming Xu, Xuejiao Deng, Wenxue Chi
Published 2021-02-01Get full text
Article -
9
-
10
-
11
Oxylipins in Aqueous Humor of Primary Open-Angle Glaucoma Patients by Jianming Xu, Kewen Zhou, Changzhen Fu, Chong-Bo Chen, Yaru Sun, Xin Wen, Luxi Yang, Tsz-Kin Ng, Qingping Liu, Mingzhi Zhang
Published 2024-09-01Get full text
Article -
12
Rhizosphere-triggered viral lysogeny mediates microbial metabolic reprogramming to enhance arsenic oxidation by Xinwei Song, Yiling Wang, Youjing Wang, Kankan Zhao, Di Tong, Ruichuan Gao, Xiaofei Lv, Dedong Kong, Yunjie Ruan, Mengcen Wang, Xianjin Tang, Fangbai Li, Yongming Luo, Yongguan Zhu, Jianming Xu, Bin Ma
Published 2025-04-01Get full text
Article -
13
Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study by Yong Xie, Conghua Song, Hong Cheng, Canxia Xu, Zhenyu Zhang, Jiangbin Wang, Lijuan Huo, Qin Du, Jianming Xu, Ye Chen, Xiaomei Zhang, Guoxin Zhang, Guibin Yang, Xiuli Zuo, Tao Guo, Yapi Lu, Fen Wang, Xuehong Wang, Kun Zhuang, Shiyao Chen, Wenzhong Liu, Nonghua Lu
Published 2020-01-01Get full text
Article -
14
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial by Chuanhua Zhao, Yanqiao Zhang, Gang Wang, Jinfang Zheng, Weiqing Chen, Zheng Lu, Li Zhuang, Shanzhi Gu, Lei Han, Zhendong Zheng, Zujiang Yu, Yongsheng Yang, Hongmei Sun, Xiaoyong Wei, Ying Cheng, Hailan Lin, Bo Zhu, Guicheng Wu, Kaijian Lei, Wei Wang, Yuwen Wang, Kehe Chen, Ximing Xu, Cuiping Zheng, Yanzhi Bi, Sijuan Ding, Jingdong Zhang, Wei Li, Hailong Liu, Jun Wang, Xianling Liu, Yangfeng Du, Lianming Cai, Jingran Wang, Zhanxiong Luo, Baocai Xing, Jie Shen, Lin Yang, Jianbing Wu, Ou Jiang, Zhigang Peng, Xiuli Liu, Bangwei Cao, Liangfang Shen, Aibing Xu, Aimin Li, Shaojun Chen, Ting Fu, Jian Chen, Chuan Jin, Lei Zhang, Jun Lv, Chengwu Zhang, Xiaoman Zhang, Yu Wang, Huo Su, Qiang Zhou, Wenlin Gai, Liangzhi Xie, Jianming Xu
Published 2025-08-01Get full text
Article